Literature DB >> 26902878

Apparent diffusion coefficient value is a strong predictor of unsuspected aggressiveness of prostate cancer before radical prostatectomy.

Raphaele Renard Penna1,2, Geraldine Cancel-Tassin3,4, Eva Comperat3,4,5, Pierre Mozer6, Priscilla Léon3,6, Justine Varinot3,5, Morgan Roupret3,4,6, Marc-Olivier Bitker3,6, Olivier Lucidarme7, Olivier Cussenot3,4,6,8.   

Abstract

PURPOSE: To evaluate the use of multiparametric MRI (mp MRI) parameters in order to predict prostate cancer aggressiveness as defined by pathological Gleason score or molecular markers in a cohort of patients defined with a Gleason score of 6 at biopsy.
METHODS: Sixty-seven men treated by radical prostatectomy (RP) for a low grade (Gleason 6) on biopsy and mp MRI before biopsy were selected. The cycle cell proliferation (CCP) score assessed by the Prolaris test and Ki-67/PTEN expression assessed by immunohistochemistry were quantified on the RP specimens.
RESULTS: 49.25 % of the cancers were undergraded on biopsy compared to the RP specimens. Apparent diffusion coefficient (ADC) < 0.80 × 10(-3) mm(2)/s (P value 0.003), Likert score >4 (P value 0.003) and PSA density >0.15 ng/ml/cc (P value 0.035) were significantly associated with a higher RP Gleason score. Regarding molecular markers of aggressiveness, ADC < 0.80 × 10(-3) mm(2)/s and Likert score >4 were also significantly associated with a positive staining for Ki-67 (P value 0.039 and 0.01, respectively). No association was found between any analyzed MRI or clinical parameter and the CCP score.
CONCLUSION: Decreasing ADC value is a stronger indicator of aggressive prostate cancer as defined by molecular markers or postsurgical histology than biopsy characteristics.

Entities:  

Keywords:  Biological markers; Biopsy; Diffusion magnetic resonance imaging; Prognosis; Prostatic neoplasms

Mesh:

Substances:

Year:  2016        PMID: 26902878     DOI: 10.1007/s00345-016-1789-3

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  30 in total

1.  Clinical utility of apparent diffusion coefficient (ADC) values in patients with prostate cancer: can ADC values contribute to assess the aggressiveness of prostate cancer?

Authors:  Yasushi Itou; Katsuyuki Nakanishi; Yoshifumi Narumi; Yasuko Nishizawa; Hideaki Tsukuma
Journal:  J Magn Reson Imaging       Date:  2011-01       Impact factor: 4.813

2.  p27(kip1) and Ki-67 (MIB1) immunohistochemical expression in radical prostatectomy specimens of patients with clinically localized prostate cancer.

Authors:  Kyriakos Revelos; Constantina Petraki; Alkiviadis Gregorakis; Andreas Scorilas; Panagiotis Papanastasiou; Roxane Tenta; Michael Koutsilieris
Journal:  In Vivo       Date:  2005 Sep-Oct       Impact factor: 2.155

3.  Assessment of aggressiveness of prostate cancer: correlation of apparent diffusion coefficient with histologic grade after radical prostatectomy.

Authors:  Sadhna Verma; Arumugam Rajesh; Humberto Morales; Lisa Lemen; Gordon Bills; Mark Delworth; Krish Gaitonde; Jun Ying; Ranasinghe Samartunga; Michael Lamba
Journal:  AJR Am J Roentgenol       Date:  2011-02       Impact factor: 3.959

4.  Prostate Imaging Reporting and Data System and Likert Scoring System: Multiparametric MR Imaging Validation Study to Screen Patients for Initial Biopsy.

Authors:  Raphaëlle Renard-Penna; Pierre Mozer; François Cornud; Nicolas Barry-Delongchamps; Eric Bruguière; Daniel Portalez; Bernard Malavaud
Journal:  Radiology       Date:  2015-01-19       Impact factor: 11.105

5.  Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer.

Authors:  Thomas Hambrock; Diederik M Somford; Henkjan J Huisman; Inge M van Oort; J Alfred Witjes; Christina A Hulsbergen-van de Kaa; Thomas Scheenen; Jelle O Barentsz
Journal:  Radiology       Date:  2011-05       Impact factor: 11.105

6.  Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer.

Authors:  M C Benson; I S Whang; A Pantuck; K Ring; S A Kaplan; C A Olsson; W H Cooner
Journal:  J Urol       Date:  1992-03       Impact factor: 7.450

7.  Final outcomes of patients with low-risk prostate cancer suitable for active surveillance but treated surgically.

Authors:  Mark Louie-Johnsun; Mischel Neill; Karien Treurnicht; Michael Jarmulowicz; Christopher Eden
Journal:  BJU Int       Date:  2009-05-07       Impact factor: 5.588

8.  ESUR prostate MR guidelines 2012.

Authors:  Jelle O Barentsz; Jonathan Richenberg; Richard Clements; Peter Choyke; Sadhna Verma; Geert Villeirs; Olivier Rouviere; Vibeke Logager; Jurgen J Fütterer
Journal:  Eur Radiol       Date:  2012-02-10       Impact factor: 5.315

9.  Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort.

Authors:  J Cuzick; D M Berney; G Fisher; D Mesher; H Møller; J E Reid; M Perry; J Park; A Younus; A Gutin; C S Foster; P Scardino; J S Lanchbury; S Stone
Journal:  Br J Cancer       Date:  2012-02-23       Impact factor: 7.640

10.  Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer.

Authors:  J Cuzick; Z H Yang; G Fisher; E Tikishvili; S Stone; J S Lanchbury; N Camacho; S Merson; D Brewer; C S Cooper; J Clark; D M Berney; H Møller; P Scardino; Z Sangale
Journal:  Br J Cancer       Date:  2013-05-21       Impact factor: 7.640

View more
  3 in total

1.  PRECISION MANAGEMENT OF LOCALIZED PROSTATE CANCER.

Authors:  David J VanderWeele; Baris Turkbey; Adam G Sowalsky
Journal:  Expert Rev Precis Med Drug Dev       Date:  2016-12-12

2.  Value of MRI texture analysis for predicting new Gleason grade group.

Authors:  Xiaojing He; Hui Xiong; Haiping Zhang; Xinjie Liu; Jun Zhou; Dajing Guo
Journal:  Br J Radiol       Date:  2021-03-11       Impact factor: 3.039

3.  Signal Intensity of High B-value Diffusion-weighted Imaging for the Detection of Prostate Cancer.

Authors:  Rezaeian A; Tahmasebi Birgani M J; Chegeni N; Sarkarian M; Hanafi M Gh; Akbarizadeh Gh
Journal:  J Biomed Phys Eng       Date:  2019-08-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.